Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Leuk Lymphoma. 2015 Mar 30;56(10):2793–2802. doi: 10.3109/10428194.2015.1018248

Table VIII.

Decitabine pharmacokinetics parameters.

PK parameter Day 1 Day 5
Sequential schedule: decitabine 20 mg/m2/day (n = 3)
    Mean Cmax (ng/mL) (SD) 137.1 (126.4) 129.9 (87.1)
    Mean AUCt (ng·h/mL) (SD) 102 (76.1) 107.1 (67.3)
    Mean AUCinf (ng·h/mL) (SD) 105.4 (77.3) 111 (66.2)
    Mean t1/2 (h) (SD) 0.36 (0.05) 0.42 (0.18)
    Mean CL (L/h/m2) (SD) 254.8 (134.3) 226.2 (121.6)
Concurrent schedule: decitabine 20 mg/m2/day (n = 6)
    Mean Cmax (ng/mL) (SD) 192.6 (164.1) 235.9 (187.5)
    Mean AUCt (ng·h/mL) (SD) 149.1 (95.8) 165.7 (85.8)
    Mean AUCinf (ng·h/mL) (SD) 152 (96.6) 169.5 (85.2)
    Mean t1/2 (h) (SD) 0.36 (0.12) 0.40 (0.17)
    Mean CL (L/h/m2) (SD) 202.8 (153.7) 139.6 (55.1)

PK, pharmacokinetics; Cmax, maximum plasma concentration; SD, standard deviation; AUCt, area under the plasma decitabine concentration versus time curve to the last sampling time; AUCinf, area under the plasma decitabine concentration versus time curve from zero to infinity; t½, terminal half-life; CL, clearance.